long intergenic non-protein coding RNA 1779Genealiases: []
Q-omics provides the consensus-scored LINC01779 profile across patient tissues and cancer cell-line models. LINC01779 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LINC01779 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, LINC01779 RNA expression shows 8,477 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, KIRC, and TGCT as cancer lineages where LINC01779 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01779 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01779 survival associations across molecular data types. LINC01779 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01779 RNA expression–survival associations across cancer types. High LINC01779 expression shows unfavorable associations in ACC, LGG, GBM and LUSC, but favorable associations in MESO and SARC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for LINC01779 RNA expression.
This table summarizes LINC01779 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01779. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01779 shows lower tumor expression in KIRC, THCA, BLCA, LUSC, LUAD and KIRP. The KIRC box plot shows higher LINC01779 RNA expression in normal versus tumor tissue (log2 FC = −0.186, t-test p < 0.001).
This table shows molecular features associated with LINC01779 in patient tissues and cancer cell lines. In patient samples, LINC01779 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
